|[February 03, 2014]
bioTheranostics' New bioT3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing with Integration of Next Generation Sequencing
SAN DIEGO --(Business Wire)--
Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite
of genomic-based tests that provide personalized diagnostic information
and therapeutic guidance for metastatic cancer patients across the
continuum of care.
The commercial launch of Next Generation Sequencing (NGS), in
conjunction with bioTheranostics' suite of cancer assays rebranded as
bioT3 Metastatic Cancer Solution, represents a significant milestone in
the company's continued efforts to deliver the right information at the
right time to help patients receive the right therapy. The bioT3 product
CancerTYPE ID®, a proprietary and
industry leading molecular classifier for accurate diagnosis of tumor
type and subtype. The CancerTYPE ID assay is supported by rigorous
clinical evidence confirming its diagnostic accuracy, clinical
utility, and impact on patient outcomes.
CancerTARGET ID, tumor-specific biomarker profiles for
selection of on-label targeted therapies (CancerTARGET ID was
previously marketed as PRÉCIS® Precision Medicine).
CancerTREATMENT ID, the newest product under bioT3, combines
NGS and multi-platform predictive biomarkers for a comprehensive
approach to identify potential treatment options. The NGS technology
uses targeted sequencing of a tumor's DNA to simultaneously analyze 50
cancer-related gens for mutations that may be driving tumor growth.
According to Richard Ding, CEO of bioTheranostics, the launch of NGS and
the bioT3 suite of molecular assays expands the company's market
leadership position, allowing it to offer a complete genomic solution
for metastatic cancer patients.
"Patients with metastatic cancers are among the most challenging for
physicians to diagnose and treat," Ding said. "Timely, accurate, and
definitive diagnosis is the critical first step in personalized medicine
for these patients. CancerTYPE ID continues to expand its market
leadership role and has been utilized by more than 4,000 oncologists in
clinical practice. At the same time, physicians also need tools to guide
the selection of the most effective targeted therapies in order to
improve outcomes and survival. With the addition of Next Generation
Sequencing integrated with the existing biomarker panels, we now provide
a comprehensive range of genomic tests for metastatic cancer. The name
bioT3 creates a unified brand that more accurately represents this suite
of tests and our rational approach to metastatic cancer
management-offering one source for metastatic cancer solutions that
provide actionable information to help address unmet medical needs."
bioT3 is available now, and clinicians can order it by calling
bioTheranostics' client service line at (877) 886-6739. For more
information about the company's bioT3 Metastatic Cancer Solution, visit biotheranostics.com.
Inc., is the leading solution provider for metastatic cancer
management, leveraging its unique expertise in gene expression profiling
to develop a growing array of molecular diagnostic tests for cancer
patients. The company operates a CLIA-certified, CAP-accredited
diagnostic laboratory to perform its proprietary tests under the bioT3
Metastatic Cancer Solution brand: CancerTYPE
ID®, CancerTARGET ID, and CancerTREATMENT ID. It also
offers the Breast
Cancer IndexSM, which quantifies risk of recurrence of
estrogen receptor-positive, lymph node-negative breast cancer.
bioTheranostics, a bioMérieux company, is based in San Diego.
[ Back To TMCnet.com's Homepage ]